National Health (Pharmaceutical Benefits) Regulations - Determination under regulation 18 (16/07/1996)

Overview

The National Health Act 1953 was enacted by the Australian Parliament to provide a framework for the administration of national health services and to facilitate the coordination of health care delivery across the country. A significant gap it addressed was the need for a structured approach to providing subsidised prescription medications to the public, which was realised through the Pharmaceutical Benefits Scheme (PBS). This legislative instrument, specifically the National Health (Pharmaceutical Benefits) Regulations, aims to establish the framework for determining the rates and conditions for payments associated with pharmaceutical benefits provided under the Act. The policy objective is to ensure that the Commonwealth’s payments for these benefits are set at appropriate rates and subject to relevant conditions, thereby maintaining the financial sustainability of the PBS and ensuring equitable access to necessary medications for all Australians.

Scope and Application

The Pharmaceutical Benefits Determination under the National Health (Pharmaceutical Benefits) Regulations operates within the framework of the National Health Act 1953, and it applies to approved pharmacists who supply pharmaceutical benefits to medical practitioners for the purposes outlined in section 93 of the Act. This Determination sets the rates at which the Commonwealth pays for these benefits based on the Commonwealth price ascertained in accordance with the relevant provisions of the National Health Act. Additionally, it ensures that the payments made for pharmaceutical benefits supplied to medical practitioners are subject to the same conditions that apply to other pharmaceutical benefits, thereby maintaining consistency across different types of pharmaceutical supplies. The legislation applies nationally and covers the entire Commonwealth of Australia, ensuring uniform standards and payments across all states and territories. There are no specific exclusions or thresholds mentioned in this Determination, but it does incorporate conditions specified under the Act, which may be further elaborated through subordinate instruments.

Key Provisions

This Determination, under regulation 18 of the National Health (Pharmaceutical Benefits) Regulations, establishes the terms and conditions for the payment of pharmaceutical benefits by the Commonwealth to approved pharmacists. Specifically, section 3 of the Determination outlines that the Commonwealth will pay an approved pharmacist the price of a pharmaceutical benefit supplied to a medical practitioner, as determined by the relevant provisions of the National Health Act 1953. This payment is tied to the Commonwealth price ascertained according to the determination under paragraph 98B(1)(a) of the National Health Act 1953 in force at the time the benefit is supplied. Furthermore, section 4 stipulates that the payment conditions for these pharmaceutical benefits supplied to medical practitioners will be subject to the same terms and conditions that apply to the supply of benefits to other recipients, in accordance with the provisions under paragraph 98C(1)(b) of the National Health Act 1953. The Act imposes several obligations on the parties involved, particularly on approved pharmacists who are to receive payments from the Commonwealth. They must ensure that the pharmaceutical benefits supplied to medical practitioners are in line with the conditions stipulated in the Determination and the relevant sections of the National Health Act 1953. Additionally, pharmacists must adhere to the payment rates and conditions established by the Commonwealth price, which is determined in accordance with paragraph 98B(1)(a) of the Act. The Act also requires pharmacists to maintain records and documentation to substantiate the pharmaceutical benefits supplied and the corresponding payments received from the Commonwealth. Breach of the conditions set out in the Determination and the Act can result in various consequences. While the Determination itself does not explicitly detail penalties for non-compliance, the National Health Act 1953 and the Pharmaceutical Benefits Scheme provide for potential offences, penalties, and consequences. For instance, under the Act, individuals or entities that engage in fraudulent practices or misrepresent facts to obtain pharmaceutical benefits may face criminal charges. Such offences can lead to substantial fines and imprisonment, with the severity of penalties depending on the nature and extent of the offence. Additionally, civil consequences may include the recovery of overpayments and legal costs. The specific penalties for breaches of the Act and Regulations are detailed in the relevant sections of the National Health Act 1953 and associated guidelines.